<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-IO2SKYBC/73631510-6682-429c-a98e-554622f5d441/PDF"><dcterms:extent>115 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-IO2SKYBC/cc4c421f-eeb9-4c75-b12a-d81f80012dec/TEXT"><dcterms:extent>41 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-IO2SKYBC"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2015</dcterms:issued><dc:creator>Ferk, Polonca</dc:creator><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:66</dc:format><dc:format xml:lang="sl">str. 218-226</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID:512498744</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-IO2SKYBC</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">dapoksetin</dc:subject><dc:subject xml:lang="en">dapoxetine</dc:subject><dc:subject xml:lang="en">erectile dysfunction</dc:subject><dc:subject xml:lang="sl">erektilna disfunkcija</dc:subject><dc:subject xml:lang="sl">farmakoterapija</dc:subject><dc:subject xml:lang="en">pharmacotherapy</dc:subject><dc:subject xml:lang="en">phosphodiesterase type 5 inhibitors</dc:subject><dc:subject xml:lang="en">premature ejaculation</dc:subject><dc:subject xml:lang="sl">prezgodnja ejakulacija</dc:subject><dc:subject xml:lang="sl">zaviralci fosfodiesteraze tipa 5</dc:subject><dc:subject rdf:resource="http://www.wikidata.org/entity/Q701216" /><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Zdravljenje erektilne disfunkcije in prezgodnje ejakulacije| Treatment of erectile dysfunction and premature ejaculation|</dc:title><dc:description xml:lang="sl">Erectile dysfunction and premature ejaculation are the most common male sexual disorders and an increasing health problem in developed countries. Etiopathogenesis of the two disorders is multifactorial and includes several biological and psycological factors. Pharmacological, psychological and/or surgical treatment approaches depend on the type and severity of the disorder. Phosphodiesterase type 5 inhibitors are the drugs of choice in pharmacotherapy of erectile dysfunction. At present, dapoxetine, a short-acting selective serotonin reuptake inhibitor, is the only drug indicated to treat premature ejaculation. Several promising therapeutic approaches for treating male sexual dysfunction are being investigated, including stem cells and gene therapy</dc:description><dc:description xml:lang="sl">Erektilna disfunkcija in prezgodnja ejakulacija sta najpogostejši spolni motnji pri moških in naraščajoči zdravstveni problem v razvitem svetu. Etiopatogeneza obeh motenj je večfaktorska, kombinacija različnih bioloških in psiholoških dejavnikov. Zdravljenje je farmakološko, psihološko in/ali kirurško, odvisno od vrste in resnosti motnje. V farmakoterapiji erektilne disfunkcije so zdravila prvega izbora zaviralci fosfodiesteraze tipa 5. Prezgodnja ejakulacija je uradna indikacija le za dapoksetin, kratkodelujoči specifični zaviralec ponovnega privzema serotonina. Za zdravljenje spolne disfunkcije pri moškem so v razvoju obetavni terapevtski pristopi, vključno z zdravljenjem z zarodnimi celicami in genskim zdravljenjem</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-IO2SKYBC"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-IO2SKYBC" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-IO2SKYBC/73631510-6682-429c-a98e-554622f5d441/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-IO2SKYBC/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-IO2SKYBC" /></ore:Aggregation></rdf:RDF>